Discovering new drugs is a laborious and expensive process, but VR is helping make it significantly faster and cheaper.


Interested in the future and want to experience even more?! eXplore More.

Virtual Reality (VR), the same technology that’s revolutionising video games and cancer treatments by letting doctors literally “fly through cancers,” is being used to develop new drugs and fight some of the world’s deadliest diseases. And in time, as Artificial Intelligence (AI) augments and takes over from human scientists, from predicting the outcomes of organic reactions to creating complex molecules, this same technology could one day help AI’s discover drugs millions of times faster than we do today by using it to run billions of drug simulations an hour.

Chemists at C4X Discovery have announced that they are using the VR technology behind popular game Fortnite to visualize the structure of complex molecules, and that the tool, called 4Sight, has already been used to create a drug that is now in development to treat addiction. Biochemists are also using the technology to develop drugs to tackle other diseases, such as cancer and Parkinson’s.


Charity fundraisers go virtual as Ready Player Golf tournament tees off


Scientists traditionally used physical models to visualize drugs. But 4Sight allows drug developers to grab hold of virtual molecules and see how they move and respond to stimuli.


A brief example of how it works

The key to drug design is finding the right shape for the molecule to fit inside the targeted protein pocket. If you get the wrong shape, the molecule could fail to attach or even lodge in a different pocket, causing side effects.

“Moving molecules around that are very complicated is so much easier by grabbing them than by trying to use a mouse on a keyboard,” says Craig Fox, chief scientific officer at C4X Discovery.


A new DNA tool is speeding up vaccine development by a million fold


The company claims that the technology could help to reduce the margin of error during the drug discovery process and enable scientists in different locations to work on drug models in the same virtual room.

“It takes about 10 to 12 years to take a drug from the concept to the market,” says Fox. “It’s often described as trying to find a needle in a haystack.”

It’s also exceedingly expensive. It costs $2.6 billion on average to develop a new prescription medicine that gains market approval, according to the Tufts Center for Study of Drug Development, so anything that helps speed up the development process and make it less laborious for scientists is welcome. That’s why C4X Discovery hired former video game developer Phil Muwanga for the job of lead coder.


DNA based marketing is becoming a reality, and brands are cashing in


“The software is the same as a game,” says Muwanga, “we have a user base, we’re trying to get them to do tasks over and over again. And we’re trying to do it in a fun and intuitive fashion.”

4Sight enables scientists to visualize the unique 4D data, that measures space and time as well as length, width and depth, that C4X Discovery has accumulated on small drug molecules.

“We are making a scientific tool that scientists will use to improve their daily lives,” says Muwanga. “That being said I am from the games industry and I do treat this as a game — people interact with it in the same way.”

VR has shown its potential in other areas of health care. It’s been used as a tool for medical training, with students learning about the human anatomy through simulation. Surgeons can use it to prepare for complicated surgeries, and it’s even been used as a tool for pain relief.


Researchers 3D printed a working spinal chord implant in 1.6 seconds


The global market for artificial and virtual reality in health care is projected to reach $5.1 billion by 2025, according to a 2017 report by Grand View Research, and even the biggest pharma companies recognize potential of virtual reality tools. Novartis, for example, is also using tit in the drug design process, and Pfizer has experimented with applications from clinical trial design to manufacturing.

“We believe immersive technologies can in the future provide cognitive behavioral assistance and even telehealth,” says Jim Mangione, Pfizer’s director of emerging technologies.

About author

Matthew Griffin

Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.

Your email address will not be published. Required fields are marked *